Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/


No comments yet.
First Name
Enter this word:

Related Stories

alt_text WHO Head Praises Hadassah Hospital

Director of the World Health Organization praises Hadassah's pediatric hemato-oncology ward.


Wednesday, Mar 14 2018

A Record Year for Transplants at Hadassah

The Hadassah Medical Organization completed the past year with a record number of transplants in its Transplantation Unit, one of the largest and most active in Israel.


Thursday, Mar 8 2018

Hadassah Performs Rare Operation on Baby About to be Born

A baby suffering from a complex congenital disorder called Stickler Syndrome was delivered successfully following the performance by a Hadassah Medical Organization multidisciplinary team of a rare operation to unblock its air passages.


Thursday, Mar 8 2018

Hadassah Physicians Travel to Mexico to Repair Cleft Palates

This week, a team of Hadassah physicians are performing surgery on children with cleft palates in Mexico. This is a part of the continuing impact that Hadassah is having on health in Mexico.


Donation Questions


(800) 928-0685

Membership Questions


(800) 664-5646

Missions Department


(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005


More ›

Show More